Genting Xinyao announced today that its new drug clinical trial application for its generic off-the-shelf tumor therapeutic vaccine EVM14 injection has been officially accepted by the Drug Evaluation Center of the China Drug Administration. EVM14 became the company's first mRNA cancer therapeutic vaccine to achieve “double reporting by the China National Drug Administration and the US Food and Drug Administration”. In March 2025, EVM14's new drug clinical trial application was approved by the US Food and Drug Administration.

Genting Xinyao announced today that its new drug clinical trial application for its generic off-the-shelf tumor therapeutic vaccine EVM14 injection has been officially accepted by the Drug Evaluation Center of the China Drug Administration. EVM14 became the company's first mRNA cancer therapeutic vaccine to achieve “double reporting by the China National Drug Administration and the US Food and Drug Administration”. In March 2025, EVM14's new drug clinical trial application was approved by the US Food and Drug Administration.